About BioCardia

We are developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases.

Our Mission: To improve the lives of patients with cardiovascular and pulmonary diseases through the development of meaningful therapeutics

Our Pipeline: Our lead therapeutic candidate is FDA designated "Breakthrough" investigational CardiAMP™ Cell Therapy, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - ischemic heart failure (BCDA-01)  and chronic myocardial ischemia (BCDA-02).

The Company’s second therapeutic platform, its Allogeneic MSC platform, an investigational culture expanded bone marrow derived allogenic or “off the shelf” cell therapy mesenchymal stem cells for the treatment of heart failure patients (BCDA-03) and acute respiratory distress syndrome (BCDA-04).



press releases

18 Sep
2024 BioCardia Regains Full Compliance with Nasdaq Listing Requirements
09 Sep
2024 BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
30 Aug
2024 BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
29 Aug
2024 BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
21 Aug
2024 FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
13 Aug
2024 BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS